Mon patient sous bithérapie anti-plaquettaire doit bénéficier d’une intervention. Quid ?

Hermans, Cédric;Lambert, Catherine
(2017) Louvain médical — Vol. 136, n° 8, p. 487-494 (2017)

Files

2017_Hermans_Lmed_136_487-494.pdf
  • Restricted Access
  • Adobe PDF
  • 956.38 KB
Request a copy

Details

Authors
Abstract
(en) [My patient under dual antiplatelet therapy has to undergo surgery: what to do?] An increasing number of patients benefit from a dual antiplatelet therapy combining a low dose of acetylsalicylic acid and a platelet adenosine diphosphate (ADP) receptor antagonist (Clopidogrel, Prasugrel, Ticagrelor), generally indicated in presence of a coronary artery stent and/or a history of acute coronary syndrome. During invasive procedures (operations, biopsies, punctures, dental care, etc.) carried out electively or urgently, the management of this antiplatelet association is often problematic. It must weigh the thrombotic risks following their cessation against the hemorrhagic risks associated with their continuation. This brief article summarizes the practical strategies for managing antiplatelet associations during invasive procedures
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Hermans, C., & Lambert, C. (2017). Mon patient sous bithérapie anti-plaquettaire doit bénéficier d’une intervention. Quid ? Louvain médical, 136(8), 487-494. https://hdl.handle.net/2078.5/56733 (Original work published 2017)